What's new for 'JKB_daily1' in PubMed
This message contains My NCBI what's new results from the National Center for Biotechnology Information (NCBI) at the U.S. National Library of Medicine (NLM).
Do not reply directly to this message.
Sender's message: Sepsis or genomics or altitude: JKB_daily1
Sent on Friday, 2013 December 20Search: (sepsis[MeSH Terms] OR septic shock[MeSH Terms] OR altitude[MeSH Terms] OR genomics[MeSH Terms] OR genetics[MeSH Terms] OR retrotransposons[MeSH Terms] OR macrophage[MeSH Terms]) AND ("2009/8/8"[Publication Date] : "3000"[Publication Date]) AND (("Science"[Journal] OR "Nature"[Journal] OR "The New England journal of medicine"[Journal] OR "Lancet"[Journal] OR "Nature genetics"[Journal] OR "Nature medicine"[Journal]) OR (Hume DA[Author] OR Baillie JK[Author] OR Faulkner, Geoffrey J[Author]))
View complete results in PubMed (results may change over time).
Edit saved search settings, or unsubscribe from these e-mail updates.
| PubMed Results |
| 1. | N Engl J Med. 2013 Dec 12;369(24):2352-3. doi: 10.1056/NEJMcibr1312709.Macrophage accumulation in atherosclerosis.Parks BW, Lusis AJ. |
| PMID: 24328470 [PubMed - indexed for MEDLINE] | |
| Related citations | |
 |
| 2. | N Engl J Med. 2013 Dec 12;369(24):2294-303. doi: 10.1056/NEJMoa1311386. Epub 2013 Nov 19.A randomized trial of genotype-guided dosing of warfarin.Pirmohamed M, Burnside G, Eriksson N, Jorgensen AL, Toh CH, Nicholson T, Kesteven P, Christersson C, Wahlström B, Stafberg C, Zhang JE, Leathart JB, Kohnke H, Maitland-van der Zee AH, Williamson PR, Daly AK, Avery P, Kamali F, Wadelius M; EU-PACT Group.Collaborators: Barallon R, de Boer A, Daly A, Haschke-Becher E, Kamali F, Maitland-van der Zee AH, Redekop K, Stingl J, Manolopoulos VG, Pirmohamed M, Rosendaal FR, Wadelius M. Author information: Comment in
AbstractBACKGROUND:The level of anticoagulation in response to a fixed-dose regimen of warfarin is difficult to predict during the initiation of therapy. We prospectively compared the effect of genotype-guided dosing with that of standard dosing on anticoagulation control in patients starting warfarin therapy. METHODS:We conducted a multicenter, randomized, controlled trial involving patients with atrial fibrillation or venous thromboembolism. Genotyping for CYP2C9*2, CYP2C9*3, and VKORC1 (-1639G→A) was performed with the use of a point-of-care test. For patients assigned to the genotype-guided group, warfarin doses were prescribed according to pharmacogenetic-based algorithms for the first 5 days. Patients in the control (standard dosing) group received a 3-day loading-dose regimen. After the initiation period, the treatment of all patients was managed according to routine clinical practice. The primary outcome measure was the percentage of time in the therapeutic range of 2.0 to 3.0 for the international normalized ratio (INR) during the first 12 weeks after warfarin initiation. RESULTS:A total of 455 patients were recruited, with 227 randomly assigned to the genotype-guided group and 228 assigned to the control group. The mean percentage of time in the therapeutic range was 67.4% in the genotype-guided group as compared with 60.3% in the control group (adjusted difference, 7.0 percentage points; 95% confidence interval, 3.3 to 10.6; P<0.001). There were significantly fewer incidences of excessive anticoagulation (INR ≥4.0) in the genotype-guided group. The median time to reach a therapeutic INR was 21 days in the genotype-guided group as compared with 29 days in the control group (P<0.001). CONCLUSIONS:Pharmacogenetic-based dosing was associated with a higher percentage of time in the therapeutic INR range than was standard dosing during the initiation of warfarin therapy. (Funded by the European Commission Seventh Framework Programme and others; ClinicalTrials.gov number, NCT01119300.). |
| PMID: 24251363 [PubMed - indexed for MEDLINE] | |
| Related citations | |
| |
| 3. | N Engl J Med. 2013 Dec 12;369(24):2283-93. doi: 10.1056/NEJMoa1310669. Epub 2013 Nov 19.A pharmacogenetic versus a clinical algorithm for warfarin dosing.Kimmel SE, French B, Kasner SE, Johnson JA, Anderson JL, Gage BF, Rosenberg YD, Eby CS, Madigan RA, McBane RB, Abdel-Rahman SZ, Stevens SM, Yale S, Mohler ER 3rd, Fang MC, Shah V, Horenstein RB, Limdi NA, Muldowney JA 3rd, Gujral J, Delafontaine P, Desnick RJ, Ortel TL, Billett HH, Pendleton RC, Geller NL, Halperin JL, Goldhaber SZ, Caldwell MD, Califf RM, Ellenberg JH; COAG Investigators.Collaborators: McBane RD, Metzger K, Lexvold N, Streichert-Blair A, Wysokinski W, Ransone T, Randolph J, Black J, O'Kane D, Christiansen P, Abdel-Rahman SZ, Clark CA, Snow LE, vonMarrensdorff H, Anderson KE, Nekhayeva I, Hallberg CK, Garcia C, Albright KJ, Mitchell C, Stevens SM, Woller SC, Peterson CP, Butler AR, Carlquist JF, Yale S, Kohnhorst D, Strey SK, Burmester JK, Schmelzer J, Caldwell M, Mazza JJ, Bhupathi S, Johnson JA, Lopez L, Zumberg M, Langaee T, Elewa H, Shahin M, Mohamed M, Chang SS, Mohler ER 3rd, Medenilla E, Rivera G, van Deerlin V, Fang MC, Magan Y, Shin J, Yglecias L, Wu A, Shah V, Kaatz S, Ellsworth S, Gikas H, Chitale D, Horenstein RB, Zhao RY, Shuldiner AR, Marron J, Fred-Omojole O, Kiser K, Sturpe D, Lee M, Limdi NA, Brown TM, Alexander J, Messiaen LM, Hill R, Dudley A, Muldowney JA 3rd, Neal T, Freehardt D, Vnencak-Jones C, Gujral J, Sharma G, Smith C, Best P, Elewa H, Deremer CE, Keller KJ, Liu S, Wang CY, Delafontaine P, Irimpen A, Ali G, Arain S, O'Meallie L, Martin-Schild SB, McDuffie R, Japa S, Asafu-Adjaye NO, Bowers S, Eloby-Childress S, Morrison E, Desnick RJ, Halperin JL, van der Zee S, Rothlauf E, Cohen I, Doheny DO, Blanchard L, Scott S, Ortel TL, Gleim MA, Sexton PA, Hall S, Jordan L, Billett HH, Naeem RC, Maala-Gentolia C, Gage BF, Do E, Venker B, Pendleton RC, Napoli L, Rondina M, McMillin G, Califf RM, Abdel-Rahman SZ, Anderson JL, Billett HH, Bookman E, Caldwell MD, Delafontaine P, Desnick RJ, Eby CS, Ellenberg JH, Fang MC, French B, Gage BF, Geller NL, Goldberg S, Goldhaber SZ, Gujral J, Hart RG, Hindorff LA, Horenstein RB, Johnson JA, Kimmel SE, Limdi NA, McBane RD, Manolio TA, Mohler ER 3rd, Muldowney JA 3rd, Ortel T, Pendleton RC, Rosenberg YD, Shah V, Stevens SM, Xu D, Yale S, Califf RM, Anderson JL, Gage BF, Johnson JA, Kimmel SE, Rosenberg YD, Wyse D, Ansell J, Crowther M, Deverka P, Richardson D, Tracy R, Kimmel SE, Ellenberg JH, French B, Kasner SE, Baldwin DA, Ballard S, Brensinger C, Cifelli D, Durborow M, Durborow S, Glick HA, Helker C, Jaskowiak J, Madigan RA, Rockwell K Jr, Wang X, Wang Y, Rosenberg YD, Goldberg S, Geller NL, Bursie Y, Hasan A, Iturriaga E, Xu D, Bookman E, Hindoff LA, Manolio TA, Eby CS, Porche-Sorbet R, King C, Kasner SE, Messé S, Goldhaber SZ, Halperin JL, Stevens SM. Author information: Comment in
AbstractBACKGROUND:The clinical utility of genotype-guided (pharmacogenetically based) dosing of warfarin has been tested only in small clinical trials or observational studies, with equivocal results. METHODS:We randomly assigned 1015 patients to receive doses of warfarin during the first 5 days of therapy that were determined according to a dosing algorithm that included both clinical variables and genotype data or to one that included clinical variables only. All patients and clinicians were unaware of the dose of warfarin during the first 4 weeks of therapy. The primary outcome was the percentage of time that the international normalized ratio (INR) was in the therapeutic range from day 4 or 5 through day 28 of therapy. RESULTS:At 4 weeks, the mean percentage of time in the therapeutic range was 45.2% in the genotype-guided group and 45.4% in the clinically guided group (adjusted mean difference, [genotype-guided group minus clinically guided group], -0.2; 95% confidence interval, -3.4 to 3.1; P=0.91). There also was no significant between-group difference among patients with a predicted dose difference between the two algorithms of 1 mg per day or more. There was, however, a significant interaction between dosing strategy and race (P=0.003). Among black patients, the mean percentage of time in the therapeutic range was less in the genotype-guided group than in the clinically guided group. The rates of the combined outcome of any INR of 4 or more, major bleeding, or thromboembolism did not differ significantly according to dosing strategy. CONCLUSIONS:Genotype-guided dosing of warfarin did not improve anticoagulation control during the first 4 weeks of therapy. (Funded by the National Heart, Lung, and Blood Institute and others; COAG ClinicalTrials.gov number, NCT00839657.). |
| PMID: 24251361 [PubMed - indexed for MEDLINE] | |
| Related citations | |
| |
| 4. | N Engl J Med. 2013 Dec 12;369(24):2304-12. doi: 10.1056/NEJMoa1311388. Epub 2013 Nov 19.A randomized trial of genotype-guided dosing of acenocoumarol and phenprocoumon.Verhoef TI, Ragia G, de Boer A, Barallon R, Kolovou G, Kolovou V, Konstantinides S, Le Cessie S, Maltezos E, van der Meer FJ, Redekop WK, Remkes M, Rosendaal FR, van Schie RM, Tavridou A, Tziakas D, Wadelius M, Manolopoulos VG, Maitland-van der Zee AH; EU-PACT Group.Collaborators: Barallon R, de Boer A, Daly A, Haschke-Becher E, Kamali F, Maitland-van der Zee AH, Redekop K, Stingl J, Manolopoulos VG, Pirmohamed M, Rosendaal FR, Wadelius M, Grounidis G, Kikas P, Mitrousi K , Kouroumichakis I, Maounis T, van der Wateren W, Straasheijm-Veldhuis B, Bayat S, Buikema M, Zuurhout M, Hegazy H, Dorenbos B, Beltman P, Hoeben E, Vellenga A, Karwar Z, Hasrat F, Hammoud S, Hagemans I, Berbee J, van der Meer S, Verdoorn S, Kraaijeveld J, Babajeff A, Boejharet S, Emerenciana A, el Khedr N, Aoussar A, van Hoorn L, Aziz A, Elia M, Schalekamp T, Nasser A, Sukel M, Verbeek-Janssen D, Vermaas H, Siauw M, Wessels J, Zwinderman K, Palmcrantz-Graf E, Eriksson N, Fitzmaurice D, Gurwitz D, Roes K, Bruggink M, ten Bokum B, Michorius N, Hennen J, Ondracek W, Cascorbi I, Eijkemans R, Koster R. Author information: Comment in
AbstractBACKGROUND:Observational evidence suggests that the use of a genotype-guided dosing algorithm may increase the effectiveness and safety of acenocoumarol and phenprocoumon therapy. METHODS:We conducted two single-blind, randomized trials comparing a genotype-guided dosing algorithm that included clinical variables and genotyping for CYP2C9 and VKORC1 with a dosing algorithm that included only clinical variables, for the initiation of acenocoumarol or phenprocoumon treatment in patients with atrial fibrillation or venous thromboembolism. The primary outcome was the percentage of time in the target range for the international normalized ratio (INR; target range, 2.0 to 3.0) in the 12-week period after the initiation of therapy. Owing to low enrollment, the two trials were combined for analysis. The primary outcome was assessed in patients who remained in the trial for at least 10 weeks. RESULTS:A total of 548 patients were enrolled (273 patients in the genotype-guided group and 275 in the control group). The follow-up was at least 10 weeks for 239 patients in the genotype-guided group and 245 in the control group. The percentage of time in the therapeutic INR range was 61.6% for patients receiving genotype-guided dosing and 60.2% for those receiving clinically guided dosing (P=0.52). There were no significant differences between the two groups for several secondary outcomes. The percentage of time in the therapeutic range during the first 4 weeks after the initiation of treatment in the two groups was 52.8% and 47.5% (P=0.02), respectively. There were no significant differences with respect to the incidence of bleeding or thromboembolic events. CONCLUSIONS:Genotype-guided dosing of acenocoumarol or phenprocoumon did not improve the percentage of time in the therapeutic INR range during the 12 weeks after the initiation of therapy. (Funded by the European Commission Seventh Framework Programme and others; EU-PACT ClinicalTrials.gov numbers, NCT01119261 and NCT01119274.). |
| PMID: 24251360 [PubMed - indexed for MEDLINE] | |
| Related citations | |
| |
posted by JKB @ 03:33
0 Comments
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home